Want to see ATNM full AI Analyst Report?
ATNM Stock Chart & Stats
$1.08
-$0.03(-3.48%)
At close: 4:00 PM EDT
$1.08
-$0.03(-3.48%)
Day’s Range― - ―
52-Week Range$0.74 - $1.74
Previous Close$0.86
Volume113.35K
Average Volume (3M)182.91K
Market Cap
$44.02M
Enterprise Value-$3.88
Total Cash (Recent Filing)$36.47M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)3.9
Beta1.72
Next Earnings
Nov 23, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding31,441,437
10 Day Avg. Volume167,884
30 Day Avg. Volume182,907
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.42
Price to Sales (P/S)471.40
P/FCF Ratio-1.72
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside224.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.12
Revenue Forecast (FY)$35.00M
Bulls Say, Bears Say
Bulls Say
Actimab-A IP And Manufacturing ExpansionBroader patent protection can extend the commercial defensibility of Actimab-A and its anti-CD33 platform, while additional manufacturing capacity may reduce execution constraints as clinical studies advance. Together, these developments strengthen the program’s infrastructure and potential strategic value over the next several quarters.
Conservative Leverage And Stronger EquityVery low leverage gives Actinium a relatively solid solvency position for a biotechnology company and limits the immediate burden of debt service. The increase in equity also improves capitalization, providing a stronger financial base while the company advances its clinical pipeline and seeks future funding.
Material TTM Revenue And Earnings ImprovementThe latest TTM period shows a meaningful shift from several years of heavy losses to higher revenue and positive net income. If the improvement is sustained, it could strengthen access to capital and support continued development, although the company’s historical volatility means durability still needs to be demonstrated.
Bears Say
Persistent Operating Cash BurnDeeply negative operating and free cash flow indicate that reported profitability is not currently translating into internally generated funds. Continued cash burn leaves Actinium dependent on external financing or strategic transactions to fund research and trials, creating an enduring risk to development pace and financial flexibility.
Thin And Historically Volatile ProfitabilityAn extremely thin gross margin provides little buffer to absorb operating expenses, while the history of weak and volatile margins makes the latest earnings improvement difficult to view as established. This limits confidence in sustainable profitability and could constrain the company’s ability to self-fund its pipeline.
NYSE American Compliance RiskThe ongoing failure to meet exchange financial standards creates a structural corporate risk rather than a temporary trading issue. Although the extension preserves listing access for now, failure to execute the remediation plan could lead to delisting, reduce market access, and weaken investor confidence.
Actinium Pharmaceuticals News
ATNM FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was $0.73 and its highest was $1.74 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Actinium Pharmaceuticals’s market cap is $44.02M.
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Nov 23, 2026 which is in 70 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.187 by -$0.003.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate is -0.26.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 31,441,437 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.187. Following the earnings report the stock price went down -1.77%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Currently, no hedge funds are holding shares in ATNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Actinium Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (224.07% Upside)
$3.50 (224.07% Upside)
Hedge Fund Trend
Decreased
By 50.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.
ATNM Stock 12 Month Forecast
Average Price Target
$3.50
▲(224.07% Upside)
Technical Analysis
Cellectar Biosciences
―
PDS Biotechnology
―
GT Biopharma
―
Marker Therapeutics
―
Celularity
―
Ownership Overview
7.10% Insiders
5.48% Mutual Funds
1.51% Other Institutional Investors
81.52% Public Companies and
Individual Investors